Blutdruckeinstellung und Mikroalbuminurie bei hypertensiven Typ-2-Diabetikern : Beobachtungsstudie zur Therapie mit Irbesartan bzw. Irbesartan/HCTZ

Background: Patients with type 2 diabetes and microalbuminuria have an elevated risk of developing diabetic nephropathy or cardiovascular complications. The effective ness of AT 1 blockers in particular irbesartan, in these patients has been confirmed in controlled clinical studies. Aim, Method: An observational study involving 500 general practitioners and 9057 patients was carried out to establish which therapeutic aims can be achieved under realistic day-to-day conditions. Inclusion criteria were type 2 diabetes, hypertension >140/90 mmHg and current treatment with irbesartan or irbesartan/hydrochlorothiazide (HTCZ). The observational study covered a period of 6 months. Results: A blood pressure measurement ≤ 130/80 mmHg was considered optimal, and the target blood pressure was defined as ≤ 140/90 mmHg. At the time of the baseline examination, the systolic pressure was outside the target in 80% of the patients, and outside the optimal range in 92%. At the second control measurement the respective figures were 37% and 69%. The diastolic blood pressure was outside the target pressure in 43% (initially) and in 7% (second measurement) of the patients, and outside the optimal range in 77% (initially) and 43% (second measurement). At the start of the study, microalbuminuria was exhibited by 66.5% of the patients and after 6 months in 50.9%. Conclusion: The observational study confirmed the good effect of irbesartan and irbesartan/HCTZ, and the benefit of effective medication and intensive standardized care.